Cross-Sector entity
The clearest coverage concentration is regulation: 5 of 6 stories, with the rest divided among 1 other category. Of the tracked stories, 4 of 6 also mention Alexandra Muñoz, the most common co-covered peer. That works out to roughly 2 stories per week across a 21-day span. The busiest single day carried 4.
6 verified stories tracked
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is regulation: 5 of 6 stories, with the rest divided among 1 other category. Of the tracked stories, 4 of 6 also mention Alexandra Muñoz, the most common co-covered peer. That works out to roughly 2 stories per week across a 21-day span. The busiest single day carried 4. Each carries 7 original sources on average. Negative sentiment appears in 67% of the tracked stories. We currently track 6 Cross-Sector stories that mention Robert F. Kennedy, Jr., published between July 12, 2026 and August 1, 2026.
Computed from the 6 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Robert F. Kennedy, Jr.. Shared-story counts are live from our verified record — not editorial picks.
MOU Signed Between HHS and VA
HHS Secretary Robert F. Kennedy, Jr. and VA Secretary Doug Collins sign a memorandum of understanding to advance psychedelic therapies for veterans, implementing Executive Order 14401.
The U.S. releases $600 million to Gavi after securing commitments to phase out mercury-containing vaccines affecting 72 million children yearly, marking a major policy shift with implications for global vaccination safety and equity.
Source: komonews.com · wcti12.com
HHS and VA signed an MOU to accelerate research and clinical deployment of psychedelic therapies for the 1 million veterans with serious mental illness, implementing a Trump executive order. The collaboration will focus on clinical trials, clinician training, and real-world evidence collection to fast-track FDA-approved treatments into VA care.
Source: abcnews4.com · wjactv.com
The EPA's failure to deliver a promised MAHA regulatory agenda after eight months exposes the agency to accountability pressures, including potential lawsuits and legislative oversight, while raising questions about good-faith regulatory planning.
The indefinite postponement of a formal MAHA agenda means delayed federal action on pesticides and chemicals linked to America's chronic disease epidemic, frustrating health advocates and potentially costing lives.
The EPA's simultaneous retreat from a promised health agenda and aggressive environmental deregulation highlights a hollowing out of environmental governance, raising concerns about the agency's ability to address the health impacts of climate change.
The lack of a clear MAHA framework from the EPA creates uncertainty for biotech and pharma companies navigating chemical regulations, potentially affecting R&D investment, product approvals, and market positioning for bio-based alternatives.
Source: abcnews.com · durangoherald.com
